Xtant Medical NYSEAMERICAN: XTNT raised its full-year 2026 revenue guidance after announcing a distribution agreement that moves the company into the hemostatic agent market, while first-quarter revenue declined from the prior-year period following divestitures and the loss of certain license revenue.
Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript
Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript
| Health Care Equipment & Supplies Industry | Healthcare Sector | Sean E. Browne CEO | XFRA Exchange | US98420P3082 ISIN |
| US Country | 217 Employees | - Last Dividend | 28 Jul 2014 Last Split | 19 Oct 2015 IPO Date |
Xtant Medical Holdings, Inc. focuses on developing, manufacturing, and marketing a range of regenerative medicine products and medical devices tailored for the needs of orthopedic and neurological surgeons both in the U.S. and internationally. Originating as Bacterin International Holdings, Inc., the company transitioned to its current name in July 2015, embodying a broader scope in regenerative medicine and medical device innovation. Operating from its headquarters in Belgrade, Montana, Xtant Medical Holdings, Inc. leverages cutting-edge science to foster advancements in medical treatments and patient care across various specialties including orthopedics, neurology, and more.